Phase I/II clinical trials with donor Treg for steroid-resistant GVHD (WP2)
- Workpackage leader
- Objectives of the Workpackage
To determine the safety and toxicity of administering donor regulatroy T cells to patients with steroid-resistant GVHD. In this work package, different strategies will be used in order to identify the best form of delivering donor Treg for the treatment of standard therapy-resistant GVHD. These trials will all take place in academic institutions with local supervision from the institution's Centre for Clinical Research, which will provide the necessary regulatory monitoring.
Links to clinical trials: